Prix FOB
Obtenir le dernier prix|
50 Unit Minimum Order
Pays:
USA
N ° de modèle:
-
Prix FOB:
Localité:
-
Prix de commande minimale:
-
Commande minimale:
50 Unit
Packaging Detail:
-
Heure de livraison:
-
Capacité de Fournir:
300 Unit per Week
Payment Type:
-
Groupe de produits :
-
Personne àcontacter Mr. Orchard W
100 N Howard ST STE R, Spokane, Washington 99201, USA, USA, Los Angeles, California
Bamlanivimab (LY-CoV**5) is a neutralising monoclonal antibody
intended for the treatment of mild to moderate COVID**9.
Drug Name
Bamlanivimab (LY-CoV**5)
Developer
Eli Lilly and Company
Therapy Class
Neutralising monoclonal antibody
Current Indication
Mild to moderate COVID**9
Market Sector
Infectious diseases
Development Status
US FDAs emergency use authorisation (EUA)
Bamlanivimab (LY-CoV**5) received emergency use
authorisation for the treatment of mild to moderate COVID**9 in
high-risk patients in November ***0. Credit: Eli Lilly and
Company.
| Pays: | USA |
| N ° de modèle: | - |
| Prix FOB: | Obtenir le dernier prix |
| Localité: | - |
| Prix de commande minimale: | - |
| Commande minimale: | 50 Unit |
| Packaging Detail: | - |
| Heure de livraison: | - |
| Capacité de Fournir: | 300 Unit per Week |
| Payment Type: | - |
| Groupe de produits : | - |
